Home / Health / Lung Cancer Drug Combo Extends Lives by 8 Months
Lung Cancer Drug Combo Extends Lives by 8 Months
24 Oct
Summary
- A combination therapy significantly improved survival for lung cancer patients.
- The new treatment regimen added eight months of extended life.
- The combination involves drugs from Amgen and AstraZeneca.
A significant advancement in treating an aggressive form of lung cancer has emerged from the combined efforts of Amgen Inc. and AstraZeneca Plc. Their innovative drug combination has demonstrated a remarkable survival benefit for patients.
By integrating Amgen's Imdelltra with AstraZeneca's Imfinzi, researchers observed that patients lived an average of eight months longer. This enhanced outcome surpassed the results seen when Imfinzi was administered as a standalone treatment. The findings suggest a powerful synergistic effect between the two medications.
This groundbreaking development offers a crucial new avenue for patients diagnosed with this severe type of lung cancer. The success of this combined therapy underscores the ongoing progress in oncology and provides a beacon of hope for improved patient longevity and quality of life.
